Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
about
Drug Therapy in the Progressed CML Patient with multi-TKI FailureThe Safety of Bosutinib for the Treatment of Chronic Myeloid Leukemia.Second line small molecule therapy options for treating chronic myeloid leukemia.Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib.Practical Management of Toxicities Associated With Bosutinib in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.Bosutinib in chronic myeloid leukemia: patient selection and perspectives.
P2860
Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Bosutinib shows low cross into ...... ish compassionate use program.
@en
Bosutinib shows low cross into ...... ish compassionate use program.
@nl
type
label
Bosutinib shows low cross into ...... ish compassionate use program.
@en
Bosutinib shows low cross into ...... ish compassionate use program.
@nl
prefLabel
Bosutinib shows low cross into ...... ish compassionate use program.
@en
Bosutinib shows low cross into ...... ish compassionate use program.
@nl
P2093
P2860
P356
P1476
Bosutinib shows low cross into ...... nish compassionate use program
@en
P2093
Alberto Alvarez-Larrán
Alejandra Martinez-Trillos
Ana Iglesias Pérez
Ana Sebrango
Andrés Romo Collado
Angeles Fernandez
Angeles Portero
Begoña Maestro
Concepción Boqué
Concepción Ruiz
P2860
P304
P356
10.1002/AJH.23973
P577
2015-03-30T00:00:00Z